CoChat

Functional Retroviral Vector for Gene Therapy of Xeroderma Pigmentosum Group D Patients

Carreau, Madeleine, Quilliet, Xavier, Eveno, Eric, Salvetti, Anna, Danos, Olivier, Heard, Jean-Michel, Mezzina, Mauro, Sarasin, Alain · 1995 · Human Gene Therapy
Cited by 57

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Xeroderma pigmentosum (XP) is an autosomal recessive genetic disorder characterized by an increased frequency of skin cancer following minimal sunlight exposure. Cells isolated from XP patients are also hypersensitive to UV rays and UV-like chemicals. This sensitivity is directly related to a defect in the early steps of nucleotide excision repair (NER) of damaged DNA. No efficient treatment is available for this disease and skin cancer prevention can only be achieved by strict avoidance of sunlight exposure. Thus, we are developing a model for gene therapy in XP, particularly for patients belonging to group D. We report here the construction of a retroviral vector (LXPDSN) containing the XPD (ERCC2) cDNA, which fully complements the DNA repair deficiency of primary skin fibroblasts. Efficient integration, mRNA synthesis, and protein expression of the XPD gene were obtained in all LXPDSN-transduced XP-D fibroblasts tested. Full correction of the DNA repair defect was observed with all DNA repair assays used, such as an increased survival after UV-radiation of the transduced cells, a normal level of DNA repair synthesis (UDS), and the reactivation of a UV-irradiated reporter vector. This retroviral vector will be used to modify keratinocytes genetically to produce repair proficient reconstituted skin for engraftment to XP patients. The first step toward gene therapy for the DNA repair disease xeroderma pigmentosum (XP) has been established by Carreau et al. They report the construction of a retroviral vector containing one of the DNA repair genes, the XP complementation group D previously known as ERCC2. Gene transfer was carried out on fibroblasts from two XP complementation group D patients referred to their laboratory. Complete phenotypic correction of the DNA repair defect in cells from both patients was achieved after the introduction of a functional copy of the XPD gene. This vector will then be used to modify keratinocytes to produce repair proficient reconstituted skin for engraftment at the most exposed areas. In this view, this study represents the first step toward long-term skin cancer therapy for XP patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/hum.1995.6.10-1307

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 57

Metadata

Authors
Carreau, M., Quilliet, X., Eveno, E., Salvetti, A., Danos, O., Heard, J.-M., Mezzina, M., & Sarasin, A.
Venue
Human Gene Therapy
Published
1995-10
Volume
6
Issue
10
Pages
1307-1315
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
OpenAlex
W2074476083
Cited by
57
References
3
FWCI
1.83
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Functional Retroviral Vector for Gene Therapy of Xeroderma Pigmentosum Group D Patients. https://app.cochat.ai/papers/10.1089/hum.1995.6.10-1307
The paper
Carreau, M., Quilliet, X., Eveno, E., Salvetti, A., Danos, O., Heard, J.-M., Mezzina, M., & Sarasin, A. (1995). Functional Retroviral Vector for Gene Therapy of Xeroderma Pigmentosum Group D Patients. Human Gene Therapy. https://doi.org/10.1089/hum.1995.6.10-1307

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.